Abstract | PURPOSE: METHODS: One hundred and twenty eyes of 120 patients undergoing vitreoretinal surgery were randomized to receive either topical nepafenac 0.1% (60 eyes) or placebo (60 eyes) in this investigator-masked, randomized, comparative case series. Eyes were evaluated for Day 1 postoperative inflammation and 2-, 4-, 6-, and 8-week postoperative retinal thickness and best-corrected visual acuity. RESULTS: Mean Day 1 inflammation grades of 0.95 ± 0.6 and 1.78 ± 0.7 were noted in patients taking nepafenac and placebo, respectively (P = 0.002). The nepafenac and placebo groups had mean central macular subfield thickness of 228.44 ± 29.27 μm and 236.21 ± 29.44 μm at 4 weeks (P = 0.172) and 205.35 ± 25.25 μm and 205.37 ± 24.90 μm at 8 weeks (P = 0.971), respectively. At 1 month, there was no statistically significant difference in the mean visual acuity between the nepafenac group (0.55 ± 0.16 decimal units) and placebo group (0.52 ± 0.17 decimal units). CONCLUSION:
|
Authors | Prashant Naithani, Shraddha Puranik, Naginder Vashisht, Sumeet Khanduja, Sanjeev Kumar, Satpal Garg |
Journal | Retina (Philadelphia, Pa.)
(Retina)
Vol. 32
Issue 2
Pg. 250-5
(Feb 2012)
ISSN: 1539-2864 [Electronic] United States |
PMID | 21926942
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Benzeneacetamides
- Phenylacetates
- nepafenac
|
Topics |
- Administration, Topical
- Adult
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage)
- Benzeneacetamides
(administration & dosage)
- Double-Blind Method
- Eye Pain
(prevention & control)
- Female
- Humans
- Macular Edema
(physiopathology, prevention & control)
- Male
- Pain, Postoperative
(prevention & control)
- Phenylacetates
(administration & dosage)
- Visual Acuity
(physiology)
- Vitreoretinal Surgery
|